Press Release Nokia and Taiwan Mobile extend 5G partnership to advance AI-powered networksNokia’s AirScale portfolio and AI-driven software power Taiwan Mobile’s 5G network modernization for enhanced performance, automation, and sustainability. New collaboration leverages AI across network intelligence, infrastructure, energy management and resilience to enable advanced 5G services and monetization.14 July 2026Espoo, Finland – Nokia today announced it has signed a 5G expansion agreement with Taiwan Mobile to accelerate the evolution toward AI-native mobile networks across Taiwan. The agreement reinforces Nokia’s role as a trusted long-term partner and supports Taiwan Mobile’s goals of enhancing network performance, automation, and sustainability. Under the agreement, Nokia will deploy its latest AirScale portfolio, including...

TEVOGENTevogen InitiativesWARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, August 24, 2026. The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof. Because the meeting date is more than 30 days after the one-year anniversary date of the 2025 Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934 (the “Exchange Act”) for consideration at the Annual Meeting must be received by the Company’s Secretary no later than July 23, 2026, in order to be considered timely. Such proposals must...

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company’s common stock at the amended and reduced exercise price of $6.00. The resale of the shares of common stock issuable upon exercise of the November 2025 Warrants has been registered pursuant to an effective registration statement...

PERTH, Australia, July 13, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKRY) (‘Alkane’ or ‘the Company’) is pleased to announce the latest exploration results for extension and infill drilling of the Brunswick South deposit, located 400m south of the previously mined Brunswick vein and 200m from planned underground access at its Costerfield Operation in central Victoria, Australia. Program SummaryAn additional 91 holes targeting the Brunswick South deposit have been drilled since Alkane’s previous update (ASX announcement 15 October 2025 titled ‘Costerfield Resource and Reserve Statement) Confidence in grade continuity has been supported by the drilling with the identification of a high antimony and gold grade connection between the recently discovered gold dominant zone at depth and the historical...

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial. Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients in the placebo-controlled pivotal back pain trial ensures the trial is well powered for success. Commercial manufacturing is proceeding in parallel so that we can file for approval as soon...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF THE COMPANY IN...

DODGEVILLE, Wis., July 13, 2026 (GLOBE NEWSWIRE) — Lands’ End, Inc. (Nasdaq: LE) today reported that it made the following inducement grants to Charlie Cole on July 13, 2026, in connection with his commencement of employment and appointment as Chief Executive Officer. The grants were not made under a shareholder approved equity plan and were previously described in a Current Report on Form 8-K filed by Lands’ End with the Securities and Exchange Commission on June 30, 2026. Mr. Cole’s inducement grants consist of an inducement sign-on grant of 109,361 restricted stock units, payable in the form of shares of Lands’ End, Inc. common stock (“Common Stock”), and an inducement sign-on grant of options to purchase up to 166,018 shares of Common Stock at an exercise price equal to $11.43 per share, which in each case will vest 25%, 25%...